Latest Factor VIII Stories
Twice-Weekly Prophylactic Regimen Resulted in 95% Reduction in Median Annualized Bleed Rate Compared to On-Demand Treatment SAN FRANCISCO, Dec.
DIEPENBEEK, Belgium, November 25, 2014 /PRNewswire/ -- Treatment for haemophilia A patients developing Factor VIII inhibitors Apitope, the drug discovery
- Three-year findings regarding prophylaxis versus on-demand treatment in adults with hemophilia A WHIPPANY, N.J., Sept.
Twice-Weekly Prophylactic Regimen Resulted in 95% Reduction in Median Annualized Bleed Rate Compared to On-Demand DEERFIELD, Ill., Aug.
LEVERKUSEN, Germany, June 23, 2014 /PRNewswire/ -- Bayer HealthCare (Bayer) and Dimension Therapeutics, a company focused on developing novel adeno-associated virus (AAV) gene therapy
KING OF PRUSSIA, Pa., May 2, 2014 /PRNewswire/ -- CSL Behring today announced that the first patient has been enrolled
Donated coagulation factor supports WFH Global Alliance for Progress program KING OF PRUSSIA, Pa., April 17, 2014 /PRNewswire/ --
- A volcanic mudflow.